These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22691628)

  • 1. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
    Vermersch P; Benrabah R; Schmidt N; Zéphir H; Clavelou P; Vongsouthi C; Dubreuil P; Moussy A; Hermine O
    BMC Neurol; 2012 Jun; 12():36. PubMed ID: 22691628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
    Piette F; Belmin J; Vincent H; Schmidt N; Pariel S; Verny M; Marquis C; Mely J; Hugonot-Diener L; Kinet JP; Dubreuil P; Moussy A; Hermine O
    Alzheimers Res Ther; 2011 Apr; 3(2):16. PubMed ID: 21504563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
    Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
    Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
    Tebib J; Mariette X; Bourgeois P; Flipo RM; Gaudin P; Le Loët X; Gineste P; Guy L; Mansfield CD; Moussy A; Dubreuil P; Hermine O; Sibilia J
    Arthritis Res Ther; 2009; 11(3):R95. PubMed ID: 19549290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
    Humbert M; de Blay F; Garcia G; Prud'homme A; Leroyer C; Magnan A; Tunon-de-Lara JM; Pison C; Aubier M; Charpin D; Vachier I; Purohit A; Gineste P; Bader T; Moussy A; Hermine O; Chanez P
    Allergy; 2009 Aug; 64(8):1194-201. PubMed ID: 19614621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?
    Arsenault S; Benoit RY; Clift F; Moore CS
    Mult Scler Relat Disord; 2022 Nov; 67():104164. PubMed ID: 36126539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
    Mora JS; Genge A; Chio A; Estol CJ; Chaverri D; Hernández M; Marín S; Mascias J; Rodriguez GE; Povedano M; Paipa A; Dominguez R; Gamez J; Salvado M; Lunetta C; Ballario C; Riva N; Mandrioli J; Moussy A; Kinet JP; Auclair C; Dubreuil P; Arnold V; Mansfield CD; Hermine O;
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):5-14. PubMed ID: 31280619
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients.
    Petrou P; Ginzberg A; Binyamin O; Karussis D
    Mult Scler Relat Disord; 2021 Sep; 54():103103. PubMed ID: 34243101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
    Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
    Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials.
    Hamad AA; Amer BE
    Neurol Sci; 2024 Jul; 45(7):3503-3507. PubMed ID: 38627298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
    Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
    BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
    Paul C; Sans B; Suarez F; Casassus P; Barete S; Lanternier F; Grandpeix-Guyodo C; Dubreuil P; Palmérini F; Mansfield CD; Gineste P; Moussy A; Hermine O; Lortholary O
    Am J Hematol; 2010 Dec; 85(12):921-5. PubMed ID: 21108325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.